Astellas Pharma’s strong pipeline and revenue growth support a positive outlook. See why ALPMF stock is a "Buy," driven by ...

Astellas has become the first drugmaker to bring a claudin 18.2 (CLDN18.2) targeted therapy to regulatory approval, getting a green light in Japan for Vyloy as a treatment for stomach cancer.

Astellas is to work with UK biotech Adaptimmune Therapeutics to develop allogeneic ‘off-the-shelf’ T-cell therapies for cancer. The Japanese pharma said its wholly-owned subsidiary Universal ...

Novel Modes of Treatment and Drugs Spur the Demand in the Immuno-oncology Market: Fact Report ROCKVILLE, MD, UNITED STATES, March 13, ...

Medical researchers in Japan have discovered a way to predict a potentially life-threatening side effect of cancer immunotherapy before it occurs. By analyzing cerebrospinal fluid collected ...

"As a multinational pharmaceutical company, Astellas has benefited from these supportive policies in its business growth in China, and we remain confident in the country's continuous endeavors to ...

Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an ...

A Belarusian state-owned TV station on Sept. 5 aired a special program about the supposed crimes committed by a Japanese man, but the sloppiness of the production has raised doubts about his guilt.

Italian cuisine incorporating Japanese ingredients is always a delight, especially at Il Ristorante - Niko Romito at Bvlgari Hotel Tokyo. As the author of Food Sake Tokyo and an expert in Tokyo ...